Drugs / SNH-119014
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07087262 | Jun 2025 → Mar 2026 overdue | hemoglobinopathy | ScinnoHub Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07579949 | Jun 2026 → Mar 2027 expected | thalassemia | ScinnoHub Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-11 | ScinnoHub Pharmaceutical Co., Ltd. | Regulatory 赛诺哈勃药业自主研发1类新药SNH-119014片获批开展临床试验 scinnohub.com ↗
6 月 9 日，倍特药业旗下赛诺哈勃药业（成都）有限公司（简称“赛诺哈勃药业”）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准公司自主研发的 1 类化学创新药物 SNH-119014 片开展相应临床试验，公司将按照相关规定和计划启动 I 期临床研究。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-11 | ScinnoHub Pharmaceutical Co., Ltd. | 赛诺哈勃药业自主研发1类新药SNH-119014片获批开展临床试验 scinnohub.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNH-119014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07579949 ↗ |
| Action | Activate | “oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR)” NCT07087262 ↗ |
| Modality | Small molecule | “oral small-molecule agonist” NCT07087262 ↗ |
| Route | Oral | “SNH-119014 is an oral small-molecule agonist” NCT07087262 ↗ |